Abstract
BackgroundPulmonary embolism is a known complication of coronavirus disease 2019 (COVID-19). Epidemiological population data focusing on pulmonary embolism-related mortality is limited. MethodsVeneto is a region in Northern Italy counting 4,879,133 inhabitants in 2020. All ICD-10 codes from death certificates (1st January 2018 to 31st December 2020) were examined. Comparisons were made between 2020 (COVID-19 outbreak) and the average of the two-year period 2018–2019. All-cause, COVID-19-related and the following cardiovascular deaths have been studied: pulmonary embolism, hypertensive disease, ischemic heart disease, atrial fibrillation/flutter, and cerebrovascular diseases. ResultsIn 2020, a total of 56,412 deaths were recorded, corresponding to a 16% (n = 7806) increase compared to the period 2018–2019. The relative percentage increase during the so-called first and second waves was 19% and 44%, respectively. Of 7806 excess deaths, COVID-19 codes were reported in 90% of death certificates. The percentage increase in pulmonary embolism-related deaths was 27% (95%CI 19–35%), 1018 deaths during the year 2020, compared to 804 mean annual deaths in the period 2018–2019. This was more evident among men, who experience an absolute increase of 147 deaths (+45%), than in women (+67 deaths; +14%). The increase was primarily driven by deaths recorded during the second wave (+91% in October–December). An excess of deaths, particularly among men and during the second wave, was also observed for other cardiovascular diseases, notably hypertensive disease, atrial fibrillation, cerebrovascular disease, and ischemic heart disease. ConclusionsWe observed a considerable increase of all-cause mortality during the year 2020. This was mainly driven by COVID-19 and its complications. The relative increase in the number of pulmonary embolism-related deaths was more prominent during the second wave, suggesting a possible underdiagnosis during the first wave.
Highlights
Recent studies suggested that this in crease cannot be attributed to coronavirus disease (COVID)-19-related deaths alone [1]
We retrospectively investigated time trends in COVID-19-related mor tality, as well as that of pulmonary embolism and other cardiovascular causes in this region as a proxy for other regions in high-income countries
The standard mortality statistics are derived by applying international rules that identify the underlying cause of death (UCOD) among all conditions listed in the certificate
Summary
Since the beginning of the severe acute respiratory syndrome coro navirus (SARS-CoV)-2 pandemic, a dramatic increase in the number of deaths was reported. Other studies have demonstrated a decrease in hospital admissions for acute cardiovascular disease such as acute myocardial infarction, acute heart failure, or stroke [2–4] This phenomenon is not yet fully understood. All-cause, COVID-19-related and the following cardiovascular deaths have been studied: pulmonary embolism, hypertensive disease, ischemic heart disease, atrial fibrillation/flutter, and ce rebrovascular diseases. The percentage increase in pulmonary embolism-related deaths was 27% (95%CI 19–35%), 1018 deaths during the year 2020, compared to 804 mean annual deaths in the period 2018–2019. This was more evident among men, who experience an absolute increase of 147 deaths (+45%), than in women (+67 deaths; +14%). The relative increase in the number of pulmonary embolism-related deaths was more prominent during the second wave, suggesting a possible underdiagnosis during the first wave
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.